AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 182 min read$TGTX

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

TG Therapeutics (TGTX) aims for a $1B quarterly run rate by year-end, driven by BRIUMVI's market share gains in multiple sclerosis. The company reports increased treatment-naive patient use and plans a simplified dosing approach. Subcutaneous BRIUMVI is in Phase 3 trials, targeting a 2028 approval. Weiss expects pivotal data by year-end or early 2024.

Original reporting
finance.yahoo.com
Published Sep 18, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 6:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TGTXNeutralLow
01

Why it matters

The article provides forward‑looking statements without new data, offering limited immediate trading insight.

02

Market read

Future regulatory and clinical milestones could affect the stock, but no near‑term catalyst is disclosed.

03

What to watch

Potential competition from other CD20 antibodies and payer reimbursement decisions.

Relevance 4/10Novelty 2/10Timing: future outlook over next 12‑18 months

Background

TG Therapeutics discusses pipeline milestones and market expansion for BRIUMVI, its MS drug.

Company-level read

Ticker impact

$TGTXNeutralMedium confidence
Context

Company outlines upcoming supplemental BLA filing for simplified dosing and expects Phase 3 subcutaneous data by year‑end, indicating future growth catalysts.

Expected impact

Modest upside if data confirms efficacy and filing is accepted.

Evidence & confidence

No immediate data release; impact depends on future regulatory outcomes.

Market effects

Sector

May influence broader MS therapeutics sector if dosing innovation succeeds.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

If Phase 3 data disappoints, the anticipated run‑rate could be delayed, pressuring the stock.

Key entities

  • company
    TG Therapeutics

    Biopharma developing BRIUMVI for multiple sclerosis.

Read at source← All news

Related articles

SEP 19
$TGTXMedAI 8/10

TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch

TG Therapeutics (TGTX) shares rose 5% after Bank of America raised its price target to $20 from $17, despite an 'Underperform' rating. The company launched a mid-stage trial for Briumvi in treatment-resistant schizophrenia. Analysts focus on Q2 U.S. revenue for Briumvi, with estimates around $229M, exceeding the company's $220M guidance. TGTX has gained 95% year-to-date.

stocktwits.com1 min
AUG 5
$TGTXMed

TG Therapeutics, Inc. Q2 2026 Earnings Call Summary

TG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.

yahoo.com5 min